|
Treating polycystic ovarian syndrome in adolescent girls having the normal body weight, however no metabolic-endocrine comorbidity and active and sub-compensated chronic extragenital diseases, with the use of non-hormonal preparations is ensured by prescribing two non-hormonal target herbal preparations from the first day of spontaneous or gestagen-induced menstruation: indinol 600 mg twice a day and epigallat 1,000 mg twice a day continuously over a period of 6 months. |
|
|
Invention relates to veterinary and can be applied in pig-breeding for the stimulation of exchange processes, growth activity, prevention of hypomicroelementosis and diarrhoeas of piglets. An energometabolic composition for the stimulation of exchange processes represents a water solution, which contains succinic acid, iodinol, beet molasses and sulphates of iron, copper, cobalt, zinc, with the following component content in 1000 ml of the solution: succinic acid - 10.0 g, iodinol - 250 ml, beet molasses - 300 ml, iron sulphate - 2 g, copper sulphate - 0.1 g, cobalt sulphate - 1 g, zinc sulphate - 0.3 g, water- the remaining part. |
|
|
Composition for prevention of metabolic disorders, increased growth activity in piglets Composition comprises succinic acid, trace elements in the form of sulphates of iron, copper, cobalt, zinc and additionally comprises methionine and beet-root molasses at the following content of components in 1000 ml of an aqueous solution: succinic acid - 5.0 g, beet-root molasses - 150.0 ml, methionine - 2.0 g, ferrous sulphate - 10.0 g, copper sulphate - 0.1 g, cobalt sulphate - 0.5 g, zinc sulphate - 0.5 g. |
|
|
Invention refers to the chemical-pharmaceutical industry and represents a method for producing preparation microcapsules possessing supramolecular properties by non-solvent addition differing by the fact that a preparation is iron sulphate or zinc sulphate pre-dissolved in water, whereas a coating is sodium alginate deposited from a butanol solution by adding ethanol as a non-solvent and water, which is followed by drying at room temperature. |
|
Method of treating chronic constipation and functional anorexia Invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45. |
|
|
Method of producing zinc oxide microcapsules Invention relates to microencapsulation, particularly to a method of producing zinc oxide microcapsules. The method is characterised by that the microcapsule shell used is carrageenan, wherein a weighed portion of zinc oxide in dimethylsulphoxide is mixed with a suspension of carrageenan in butanol in the presence of an E472c surfactant; ethanol is added to the obtained suspension as a precipitant; the obtained suspension is filtered and dried at room temperature. |
|
|
Compositions and methods for improving drug therapy with metal ion dependant agents Invention refers to a preparatory kit presented to a patient before administering a therapeutic botulinum toxin. The declared kit contains an additive in the form of capsules or tablets, which comprise zinc ions in the organic or inorganic form in a sufficient dose of 10mg to 400mg of elementary zinc a day, and a phytase additive in an amount of 0.8-10,000 units sufficient to be administered together with the ion zinc additive for the period of zinc ion load. The preparatory kit also comprises a package insert providing the patient with recommendations to administer the zinc ion additives and to reduce the phytate dose. |
|
What is presented is using zincatrane (Citrimin) as an agent stimulating expression of matrix RNA of tryptophanyl-tRNA-synthetase. |
|
|
Carageenan-containing aqueous antimicrobial compositions Invention refers to medicine and concerns an anhydrous antimicrobial composition containing an effective amount of an antimicrobial agent containing carageenan, which represent lambda carageenan in an amount of approximately 50% dry weight of carageenan, wherein the rest of said carageenan is other than at least one lambda carageenan, as well as a physiologically acceptable metal salt and an antiretroviral agent specified in a group consisting of non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors. |
|
Method for conservative management of parodentium Invention refers to medicine, namely to dentistry. A method for the conservative treatment of parodontium involves applying a treatment wrap prepared of zinc oxide and zinc sulphate; applying the treatment wrap is preceded by a multiple irrigation of parodontium tissues with butol solution; the treatment wrap is prepared by adding zinc oxide powder and zinc sulphate powder into butol solution and mixing them to pasty consistency; dental tissues from the vestibular and oral surfaces in the neck region are covered with a gauze drain of the diameter of 1-4mm saturated with butol solution; parodentium and dental tissues covered with the gauze drain saturated with butol solution is coated with the treatment wrap. |
|
|
Agent for preventing and treating prostatitis and prostate adenoma Invention represents an agent for preventing and treating prostatitis and prostate adenoma in the form of a capsule, which contains doxazosin, diisopropylammonium dichroloacetate, afobazol, copper glycinate, vitamin E (d-alpha tocopherol acetate), zinc glycinate; L-Glutamine; L-Alanine; L-Arginine and excipients: corn starch and talc. |
|
|
Antibacterial composition, containing 4-isopropyl-3-methylphenol and zinc ions Invention relates to an antibacterial composition and is intended for the oral cavity care. The antibacterial composition contains an antibacterial system, including a 4-isopropyl-3-methylphenol (IPMP) source of zinc ions and alkali metal C8-18 alkylsulphate and a perorally acceptable carrier or an excipient. The composition Ph constitutes from 5.5 to 7.5. |
|
Invention relates to chemical-pharmaceutical industry and represents substitute of bone transplant, containing osteogenic agent and zeolite, which contains particles, containing ion-exchange cations of metals, present in quantity, effective for stimulation of osteogenesis in patient who needs it, in which said metal cations are selected from the group, consisting of zinc ions, silver ions, copper ions and their combinations. |
|
|
Method of treating bovine digital dermatitis (dermatitis digitalis) Invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest. |
|
|
Method of treating bovine digital dermatitis Invention refers to the veterinary science and is applicable for treating bovine digital dermatitis. A method involves applying a preparation in the form of an ointment of the following formulation, wt %: veterinary copper sulphate 35-45, zinc oxide 9-11, an ointment base - the rest. The preparation is made by mixing the ingredients until smooth. The preparation is applied on the involved regions 1-2 times with or without a protective dressing. |
|
|
Invention relates to granules as a laxative, containing particles of magnesium oxide of formula Mg2+ 1-xZn2+ x)O (1) with the average diameter of secondary particles 0.1-25 mcm and apparent specific volume 3-20 ml/g. In formula (1) X represents number from 0 to 0.02, content of magnesium oxide particles constitutes from 80 to 95 wt %. Granules also include mannitol and carmellose and have the average particle diameter 0.2-0.4 mm and bulk density 0.4-0.7 g/ml. Content of particles in granules, which have particle diameter from less than 500 mcm to not less than 355 mcm, constitutes from 30 to 45 wt %, content of particles, which have particle diameter from less than 355 mcm to not less than 180 mcm constitutes from 40 to 50 wt %, content of particles, which have particle diameter from less than 180 mcm to not less than 150 mcm, constitutes from 10 to 28 wt %. |
|
External therapeutic agent for patients suffering from atopic dermatitis Agent contains 0.2% Pyriton, an emulsifier, an emollient - isopropyl myristate, and a solvent. The emulsifier is presented by glycerol cocoate PEG-7; the emollient is presented by triglycerides of caprylic and capric acids; the solvent is water. Besides, the agent additionally contains glycerol, cyclomethicone, urea, allantoin and a flavouring agent. All the ingredients of the agent are taken in certain mass ratio. |
|
|
Method of treating male sterility caused by autoimmune response to sperm cells There are used chymotrypsin 360-480 mg/day, trypsin 360-480 mg/day, papaine 900-1200 mg/day and 1,9-dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one (Inosine) 1200-1800 mg/day, zinc 7-10 mg/day, selenium 50-100 mcg/day, vitamin E - 30-400 mg/day, C - 180-500 mg/day, B-carotin - 4-10 mg/day taken orally for 2-3 weeks during a female's follicular phase. |
|
|
Mixed metal compounds applicable as antacids Invention refers to using mixed metal compounds for preparing a drug preparation for neutralisation of gastric acid or buffer action thereon, as well as for treatment of a condition or a disease related to high gastric levels of acid. The mixed metal compound is a compound of formula (I): MII 1-aMIII aObAn- c.zH2O (I), wherein MII and MIII mean a two-valence and three-valence metal respectively, An- means an n-valence anion, 0.2≤a≤0.4, 0.2≤b≤1.5, 2+a is equal to 2b+Σcn, Σcn<0.9a, and z is equal to 2 or less. According to the invention, the mixed metal compound is presented in the form of a granulated material, wherein a diametre of 50 wt % of the granules makes 106 to 1180 mcm with the material comprising 50 wt % of the mixed metal compound, 3 to 12 wt % of noncovalent water and no more than 47 wt % of an excipient on granulated material weight basis. The mixed metal compound in the form of the granulated material represents a compound of formula (I) or a compound of formula (III): MII 1-xMIII x(OH)2An- y·mH2O (III) ; wherein MII and MIII mean a two-valence and three-valence metal respectively, An- means an n-valence anion, x=Σyn, 0<x≤0.4, 0<y≤1, and 0≤m≤10. |
|
Antiseptic drug with haemostatic action, and method for preparing it Invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture. |
|
|
Product for topical application stimulating skin regeneration Invention refers to pharmaceutics and concerns a composition for topical application, stimulating the skin regeneration processes, possessing antiseptic and anti-inflammatory action for treating inflammatory (including exudative) skin diseases, containing antiseptic Dorogov's stimulator (fraction 3), zinc oxide, potato starch and salve base, with lower side effect. |
|
What is presented is a nootropic agent prepared of an inorganic (mineral) raw material. A formulation with the following proportion of the ingredients is used as the above agent, wt %: potassium chloride 98.5-78.3, magnesium sulphate 0.98-20.8, zinc sulphate 0.42-0.65 and rubidium nitrate 0.1-0.25. |
|
Preparation for soft tissue regeneration with antibacterial effect Invention refers to a powdered preparation for soft tissue regeneration with an antibacterial effect. The preparation contains 0.07-0.09 wt % of copper nanoparticles sized 30-40 nm, 0.03-0.05 wt % of zinc nanoparticles sized 30-70 nm, and low-molecular chitosan. |
|
|
Method of treating benign diseases of cervix Invention relates to medicine, namely to gynecology, and can be used for treatment of benign diseases of cervix. For this purpose rectal viferon suppositories are preliminarily introduced for ten days in dose 1000000 IU. After that, cervix is treated with solcovagin solution with 30-60 sec exposure 1-2 times during the day on the 5-7 day of the following menstrual cycle. After 4-5 days medication viferon is applied in form of gel on cervix in dose 1-2 applications per day, course length being 7-8 days. |
|
|
Invention refers to medicine and pharmacology and represents a complex compound of zinc 2-chloropropionate and 2-chloropropionic acid of general formula [Zn(CH3CHClCOO)2(CH3CHClCOOH)2], as well as a pharmaceutical composition representing a solution of said complex compound in 2-chloropropionic acid. |
|
Method of treating patients suffering pustular skin disorders Invention relates to medicine, particularly to dermatology, more specifically to methods of treating pyoinflammatory skin diseases, particularly furunculosis and acne. The method of treating the patients suffering pustular skin disorders, according to the invention, consists in the fact that the affected and surrounding skin areas are prepared with warm weak antiseptic, dried and further processed with an ointment prepared by thorough mixing on a water bath until smooth: zinc-salicylic paste, Lorinden C, gioxizone, streptocide liniment, synthomycin liniment and retinol acetate in the ratio of 3÷1÷1÷1÷0.8÷0.1 with skin treatment produced 2 times a day. The weak antiseptic is sodium bicarbonate or chamomile infusion at temperature 40-45°C. Besides, water bath temperature is to be 40-50°C, and the ointment is to be prepared is a glass or ceramic container. Face acne requires the affected area to be warmed with a vapour bath before finally applying the ointment. To prevent accidental wipe-out of ointment from the ointment treated skin, it is covered with the napkins attached to healthy skin. To enhance the effect of the ointment applications, the affected skin is exposed to UV lamp and/or sunlight for 10-30 minutes. |
|
Method of treating androgenetic alopecia Method relates to medicine, particularly to dermatology, and may be applied for treating androgenetic alopecia. That is ensured by scalp introduction of zinc hyaluronate by electroporation. Preferentially, electroporation shall be conducted by rectangular current pulses of the length of 100 microseconds, frequency 200 Hz, of sinusoidal modulation. Preferentially, a pulse trains shall make 1.5 seconds with a pause of 0.5 seconds, while an exposure length shall not exceed 18 minutes. Preferentially, current intensity shall be adjusted within the range of 0.1 to 100 V as shown by patient's subjective sensations to painfulness. Preferentially, the therapeutic course shall make min. 10 procedures with the first 6 procedures performed 3 times a week, and the following 4 procedures - 2 times a week. |
|
Method of treating psoriasis vulgaris Method relates to medicine, particularly to dermatology, and may be applied in treating psoriasis vulgaris. That is ensured by a therapy involving a combination of the hepatoprotector Phosphogliv and an external non-hormonal therapy. Phosphogliv is prescribed according to the schedule: 2.5 mg intravenously once a day for 10 days, then orally 1 capsule 3 times a day; and the non-hormonal preparation is Cinocap cream 3 times a day; the therapeutic course makes 4 weeks. |
|
|
Invention relates to medicine and deals with complex immunomodulator for prevention of malfunctions and regulation of immune system functioning (versions). Claimed is complex medication for prevention of malfunctions and regulation of immune system functioning, which is characterised by the fact, that it is made in form of capsules and contains human recombinant interferon of alpha, and/or beta, and/or gamma types, retinol palmitate, zinc sulphate monohydrate, additional substance - to 0.1 g. Also claimed is complex immunomodulator for prevention of malfunctions and regulation of immune system functioning, which is characterised by the fact that it is made in form of suppository on hydrophilic base and contains human recombinant interferon of alpha, and/or beta, and/or gamma types, retinol palmitate and/or substances, selected from a number of alpha, beta, gamma carotenes, zinc sulphate monohydrate, as well as additional substances. |
|
Invention refers to an agent exhibiting nootropic action. The declared agent contains calcium chloride, sodium chloride, ferric sulphate (II), zinc sulphate, chromium chloride (III) and potassium bromide in certain proportions. |
|
Method for correction of immunobiochemical status in ante- and postpartum cows Invention refers to veterinary science. The preparation metallosuccinate 10 ml is introduced intramuscularly three times before calving and two times after every 10 days. |
|
What is presented is an antihypoxic agent differing by the fact that it represents a complex compound of divalent zinc substituted by 3-hydroxypyridine and diorganodichalcogenide - hexakis(3-hydroxy-2-ethyl-6-methylpyridinato)[tris(dibenzylselenido)dizinc(P)pentadeca-semihydrate of formula [Zn(II)]2A6B3·15.5H2O (the same πQ1983). [Zn(II)]2A6B3·15.5H2O wherein A: B: |
|
Electrogenerating particles and use thereof Invention refers to a galvanic particle consisting of zinc, partially copper-plated. A galvanic particle size is equal to nm to 100 mcm, while copper weight therein makes 0.01-10 % of particle weight. The galvanic particles under the invention may be prepared by contact of the zinc particles and a copper salt solution. The invention also refers to a pharmaceutical composition which contains an effective amount of said galvanic particles and a bioabsorbed polymer, and to an oral dosage form containing an effective amount of the galvanic particles under the invention, and a pharmaceutically acceptable carrier. The invention also refers to a method for destruction of drug-resistant microorganisms involving contact of a microorganism and the composition containing the carrier and said galvanic particles. |
|
|
Agent for treating inflammatory oral diseases and method of treating inflammatory oral diseases Group of inventions refers to pharmacological industry and medicine, and concerns an agent for local application effective for treating inflammatory oral diseases of various aethiologies. The agent for treating inflammatory oral diseases contains a hydrophilic base presented by organic silicon glycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O or organic titanium silicone 2Si(C3H7O3)4·Ti(C3H7O3)4·22C3H8O3·88H2O, or water-soluble dimethyl silicone glycerolates (CH3)2Si(C3H7O3)2·xC3H8O3 (0,5≤x≤1); and an active therapeutic additive presented by galavit or polyoxydonium, or betaleukin, or a mixture of oil solution of vitamin E and zinc ingredient under certain proportions. A method of treating inflammatory oral diseases consists in the fact that antiseptic treatment of an involved area is followed by the introduction of said agent by application on oral mucosa or gingival surface or instillation into gingival pockets once a day for 15 min; the therapeutic course is 5-7 days. The presented agent is an accessible form for local application; it enables achieving a high therapeutic effect. |
|
|
Medication for destructuring atherosclerotic lesions, formed on walls of blood vessels Claimed is application of carbon-containing nanoparticles, representing carbon nanocapsule 10 nm in size, containing iron particles, for destructuring atherosclerotic lesions, formed on the walls of blood vessels. It is demonstrated that claimed carbon-containing nanoparticles, applied on the surface of atherosclerotic lesion, are capable of penetrating into its internal layers and modifying its structure: presence of nanoparticles in it combines with presence in it of segments of sparse collagen structures. |
|
Composition possessing analgesic, anti-inflammatory and locomotor function improving action Invention refers to a composition possessing analgesic, anti-inflammatory and locomotor function improving action. The composition contains 1-20 wt % of glucosamine sulphate, 1-10 wt % of chondroitin sulphate, 0.0001-10 wt % of methylsulphonylmethane, 0.01-5 wt % of L-proline, ascorbic acid, magnesium. The declared composition additionally contains zinc gluconate, citric acid, a sweetening agent, a flavour, a preserving agent and water. |
|
|
Combined antituberculous composition Invention refers to pharmaceutical industry, and concerns a combined therapeutic agent possessing antituberculous action. The agent is presented in a solid dosage form which contains a combination of paraaminosalicylic acid and a zinc-containing compound as an active principle, and pharmaceutically acceptable excipients. The zinc-containing compound is specified in zinc picolinate, zinc citrate, zinc acetate, zinc glycerate, zinc monomethionine, zinc aspartate, zinc hyaluronate, zinc gluconate, zinc bisvinylimidazole diacetate, zinc oxide. |
|
|
Composition, possessing adaptogenic, general tonic and working capacity-increasing acyion Invention relates to chemical-pharmaceutical industry and represents composition, which possesses adaptogenic, general tonic and working capacity-increasing action, which contains nicotineamide, alfa-tocopherol acetate, pyridoxine hydrochloride, riboflavin beta-carotene, folic acid, biotin, cyanocarbolomine, coenzyme Q10, potassium hydrogen orthophosphate, inositol, choline, soy lecithin, zinc gluconate, calcium pantothenate, thiamine hydrochloride, vitamin D, fructose, citric acid, ascorbic acid, preservative, sweetener, fragrance, water, components in composition being in specified weight ratio. |
|
|
Therapeutic agent for treating ulcer Declared invention refers to an agent for treating ulcer including as an effective ingredient composite hydrotalcite in the form of particles, which contains zinc in the form of a solid solution and presented by formula (MgaZnb)1-xAlx(OH)2(An-1)x/n·H2O, wherein An-1 means CO3 2-, SO4 2- or Cl-, n is equal to 1 or 2, and x, a, b and m have the values fulfils the following conditions 0.18≤x≤0.4, 0.1≤a≤1, 0≤b≤0,5, 0≤m<1. Said agent may be presented in the granular or fine-grained form, suspension form or tableted form. The invention also refers to a method of treating peptic ulcer by the oral introduction of an effective amount of said hydrotalcite. |
|
|
Claimed is application of complex of tris-(2-hydroxyethyl)amine with zink bis-(2-methylphenoxyacetate) [cresoxyzinkatrane] of formula (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as stimulator of cytokine activity of total triptophanyl-tRNK synthetase. Demonstrated is increase of total triptophanyl-tRNK synthetase by 50% in comparison with control in dose 5 mg/kg with intramuscular introduction during 2 months; introduction of cresoxyzinkatrane in the same dose but together (simultaneously) with cholesterol during 3 months also produces expressed effect - increase of TRSase level. |
|
Combined medicated paste for deep caries Invention refers to medicine and dentistry, namely medical products presented in the form of a paste for deep caries. The developed combined medicated paste contains 0.2 %, wt %: colophony - 5, zinc oxide - 5, uncured rubber - 1, chloroform - 5, sodium fluoride - 0.01, 20% dimexide - 5, anesthesin - 0.1, Indost-Gel+ - the rest. |
|
|
Combined medicated paste for conservative treatment of acute local pulpitis Invention refers to medicine and dentistry, namely medical products presented in the form of a paste for acute local pulpitis. The developed combined medicated paste for conservative treatment of acute local pulpitis contains, wt %: lisocyme - 5, vitamin A solution in oil - 5, zinc oxide - 20, 30% dimexide - 5, dexamethasone - 0.1, neomycin - 0.1, Collost-gel - the rest. The paste possesses high penetration strength, stimulates the repair function of a dental pulp. |
|
|
Pharmaceutical compositions glp-1 Invention refers to pharmacology and represents a pharmaceutical composition containing the GLP-1 [Aib8,35]hGLP-1 (7-36)NH2 analogue prepared together with a pharmaceutically acceptable salt of said analogue or a mixture of salt of said analogue and the analogue, said composition additionally contains a bivalent metal and/or a bivalent metal salt with the molar ratio of said GLP-1 analogue and said bivalent metal and/or bivalent metal salt in said pharmaceutical composition makes approximately 5.4:1 to approximately 1.5:1; wherein said bivalent metal represents zinc or copper, and wherein the range of the molar ratios of said salts (Aib8.35)hGLP-1 (7-36)NH2 and the GLP-1 peptide analogues makes approximately 0.5:1 to approximately 10:1. |
|
Complex antiviral medication for external application in treatment of herpes virus infections Invention relates to medicine, namely, to virology, pharmacy, and is intended for treatment of herpetic infections For this purpose applied is complex antiviral medication for external application, which contains (in wt %) recombinant interferon α - 2b (40-50) 106 IU, hyaluronic acid - 0.5-1.0, chitosan succinate - 1.0-2.0, licorice root extract - 0.2-0.5, zinc oxide - 0.8-2.0, lidocaine or dicaine - 0.8-1.0, polyethylenoxide-1500 - 5.0-7.0, anhydrous lanolin - 22.0-27.0, medical vaseline - 35.0-40.0, glycerin - 5.0-8.0, distillated water to 100,0 Medication ensures prolonged anti-inflammatory, anesthetic, wound-healing impact on herpetic affection of mucous membranes and skin, including genital herpes, opthalmo-herpes and shingles. |
|
|
Combined antituberculous pharmaceutical composition Invention refers to medicine and pharmacy, namely an antituberculous composition. The pharmaceutical composition contains sodium salt of para-aminosalicylic acid, zinc sulphate, lactose, polyvinylpyrrolidone, citric acid, stearic acid salt, carboxymethyl sodium starch, colloidal silicon dioxide and polyethylene glycol. |
|
|
Pharmaceutical composition for treatment of type 2 diabetes mellitus and medicine on its basis Invention relates to chemical-pharmaceutical industry and can be applied for treatment of type 2 diabetes mellitus. Composition containa as active substances N-(β-oxyethyl)-4,6-dimethyldihydropyrimedone-2 (xymedon) and inulin in ratio (2.5-5):(1-3). Composition can additionally contain magnesium, zinc, chromium asparaginates and can be made in form of capsules or pills. |
|
Invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment. |
|
|
Invention refers to medicine and cosmetology, and represents a bactericidal nail care polish containing a water-soluble film-forming hydroxyalkyl chitosan or carboxyalkyl chitosan material, a bactericidal agent, a polar aqueous-alcoholic solvent which as the bactericidal agent contain bentonite powders nanostructured to particle size 150 nm and less, and intercalated by metal ions Ag+ or Ag+ and Zn2+, or Cu2+ and Zn2+, or Ag+ and Cu2+ and Zn2+ which are introduced into a prepared emulsion of the film-forming material in the form of 4-10 % hydrosol; the components of the composition are taken in certain proportions, wt %, and the weight ratio parts of the mixtures of bentonite powders intercalated by metal ions is: for metal ions Ag+ and Zn2+ (1:(0.5÷1)); for metal ions Cu2+ and Zn2+ (1÷0.5):(0.5÷1); for metal ions Ag+ and Cu2+ and Zn2+ 1:(0.5):(0÷1). |
|
Improved oral compositions containing zinc citrate and/or tocopherol ingredients Group of inventions refers to medicine, namely to dentistry, and aims at desentisation, reduced calculus formation, caries and bad breath. An oral cavity contacts with an oral composition containing an active ingredient consisting of a zinc citrate agent and a potassium citrate agent where the composition has pH value ranging within approximately 6 to approximately 10. |
|
|
Pharmaceutical composition for treating prostate diseases (versions) Invention refers to medicine, namely to peptide preparations for treating prostate diseases. The pharmaceutical composition (the first version) comprises 7-60 wt % of a bioregulatory peptide complex of bovine prostate containing water-soluble peptides 9 % more, and 40-93 wt % of a chelate zinc-arginine-glycin complex. The pharmaceutical composition in the form of suppositories (the second version) contains 0.015-0.130 g of the bioregulatory peptide complex of bovine prostate and 0.086-0.200 g of the chelate zinc-arginine-glycin complex as a bioactive compound in one fat-based suppository 2.7-2.9 g. |
Another patent 2551083.